The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study

British Journal of Ophthalmology

Volumn 89, Issue 9, 2005, Pages 1166-1170

  McGwin Jr , G ^a,b,c   Hall, T A ^a   Xie, A ^a   Owsley, C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA MACULA AGE RELATED DEGENERATION; UNITED STATES;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC METHODS; FEMALE; FUNDUS OCULI; HEALTH SURVEYS; HUMANS; MACULAR DEGENERATION; MALE; SMOKING;

EID: 24144464327     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.067397     Document Type: Article

References (50)

1. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614.
2. Anderson DH, Mullins RF, Hageman GS, et al. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-31.
3. Penfold PL, Madigan MC, Gillies MC, et al. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 2001;203:385-414.
4. Hageman G, PJ L, NH VC, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20:705-32.
5. Seddon J, Gensler G, Milton R, et al. Association between C-reactive protein and age-related macular degeneration. JAMA 2004;291:704-10.
6. Klein R, Klein BE, Tomany SC, et al. Association of emphysema, gout, and inflammatory markers with long-term incidence of age-related maculopathy. Arch Ophthalmol 2003;121:674-78.
7. Johnson LV, Leitner WP, Staples MK, et al. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 2001;73:887-96.
8. Johnson LV, Ozaki S, Staples MK, et al. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 2000;70:441-9.
9. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol 1987;31:291-306.
10. Group A-REDSR. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3, Ophthalmology 2000;107:2224-32.
11. Smith W, Mitchell P, Leeder SR, et al. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 1998;116:583-7.
12. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004;111:1280-7.
13. Klein R, Klein BE, Tomany SC, et al. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 2003;110:1273-80.
14. Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-95.
15. McCarty CA, Mukesh BN, Fu CL, et al. Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol 2001;119:1455-62.
16. McCarty CA, Mukesh BN, Guymer RH, et al. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. Med J Aust 2001;175:340.
17. McGwin G Jr. Owsley C, Curcio CA, et al. The association between statin use and age related maculopathy. Br J Ophthalmol 2003;87:1121-25.
18. Hall NF, Gale CR, Syddall H, et al. Risk of macular degeneration in users of statins: cross sectional study. BMJ 2001;323:375-6.
19. van Leeuwen R, Tomany S, Wang J, et al. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. Ophthalmology 2004;111:1169-75.
20. Klein R, Klein BE, Jensen SC, et al. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2001;119:1354-9.
21. Klein R, Klein BE, Tomany SC, et al. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 2003;121:1151-5.
22. Christen WG, Glynn RJ, Ajani UA, et al. Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians. Arch Ophthalmol 2001;119:1143-9.
23. Klein R, Klein BE, Marino EK, et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology 2003;110:25-33.
24. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263-76.
25. Tell GS, Fried LP, Hermanson B, et al. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993;3:358-66.
26. Hubbard LD, Brothers RJ, King WN, et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999;106:2269-80.
27. Group. ARIC Retainal Photography Protocol, Manual 14A, and ARIC Reading Center Protocol, Manual 14B. Chapel Hill: University of North Carolina, CB#, 8030.
28. Klein R, Davis M, Magli YL, et al. Wisconsin age-related maculopathy grading system. Madison: University of Wisconsin Medical School, Department of Ophthalmology and Visual Sciences, 1991.
29. Klein R, Davis MD, Magli YL, et al. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991;98:1128-34.
30. Cushman M, Cornell ES, Howard PR, et al. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995;41:264-70.
31. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-8.
32. Klein R, Klein BE, Jensen SC, et al. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology 1999;106:1056-65.
33. Klein R, Clegg L, Cooper LS, et al. Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study. Arch Ophthalmol 1999;117:1203-10.
34. Group TEDC-CS. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1992;110:1701-8.
35. Klein R. Epidemiology. In: Berger J, Fine S, Maguire M, eds. Age-related macular degeneration. St Louis, Mo: Mosby, 1999:31-56.
36. Clemons TE, Kurinij N, Sperduto RD. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No 13. Arch Ophthalmol 2004;122:716-26.
37. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
38. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
39. Pedrinelli R, Dell'Omo G, Di Bello V, et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Tnromb Vasc Biol 2004;24:2414-19.
40. Bautista LE, Lopez-Jaramillo P, Vera LM, et al. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001;195:857-61.
41. Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005;19:149-54.
42. Sung K, JY S, BS K, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003;16:429-33.
43. Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004;53:2855-60.
44. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384-9.
45. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
46. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-600.
47. Sowers M, M J, E S, et al. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis and Cartilage 2002;10:595-601.
48. Spector TD, Hart DJ, Nandra D, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723-7.
49. Sharif M, Elson CJ, Dieppe PA, et al. Elevated serum C-reactive protein levels in osteoarthritis. Br J Rheumatol 1997;36:140-1.
50. Streilein JW, Okamoto S, Sano Y, et al. Neural control of ocular immune privilege. Ann N Y Acad Sci 2000;917:297-306.